A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer
收藏DataCite Commons2024-12-02 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006800/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate
treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a
continuous daily regimen (once per day) for one year.
提供机构：
Vivli
创建时间：
2021-04-02
